Cardio-oncology: A focus on cardiotoxicity

86Citations
Citations of this article
211Readers
Mendeley users who have this article in their library.

Abstract

Cardio-oncology is a recently developed field in cardiology aimed at significantly reducing cardiovascular morbidity and mortality and improving quality of life in cancer survivors. Cancer survival rates have been constantly increasing, mainly because of the advent of new, more potent and targeted therapies. However, many of the new therapies - along with some of the older chemotherapeutic regimens such as anthracyclines - are potentially cardiotoxic, which is reflected increasingly frequently in the published literature. Cardiotoxicity adversely affects prognosis in cancer patients, thus its prevention and treatment are crucial to improve quality and standards of care. This review aims to explore the existing literature relating to chemotherapy- and radiotherapy-induced cardiotoxicity. An overview of the imaging modalities for the identification of cardiotoxicity and therapies for its prevention and management is also provided.

Cite

CITATION STYLE

APA

Koutsoukis, A., Ntalianis, A., Repasos, E., Kastritis, E., Dimopoulos, M. A., & Paraskevaidis, I. (2018). Cardio-oncology: A focus on cardiotoxicity. European Cardiology Review , 13(1), 64–69. https://doi.org/10.15420/ecr.2017:17:2

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free